Beta Bionics price target raised to $32 from $28 at Truist

Truist raised the firm’s price target on Beta Bionics (BBNX) to $32 from $28 and keeps a Buy rating on the shares. The company posted another solid beat and raise driven by new patient start upside and a $6M FY25 revenue guidance raise, the analyst tells investors in a research note. Truist adds that the accelerated pharmacy channel shift has even bigger positive out-year estimate implications.